These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 2272712)

  • 21. Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States.
    Hayashi PH
    Int J Mol Sci; 2016 Feb; 17(2):201. PubMed ID: 26861284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International reporting on adverse drug reactions: the CIOMS project. CIOMS ADR Working Group.
    Faich GA; Castle W; Bankowski Z
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):133-8. PubMed ID: 2338366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation and Reproducibility of the Updated French Causality Assessment Method: an Evaluation by Pharmacovigilance Centres & Pharmaceutical Companies.
    Théophile H; Dutertre JP; Gérardin M; Valnet-Rabier MB; Bidault I; Guy C; Haramburu F; Hillaire-Buys D; Méglio C; Arimone Y
    Therapie; 2015; 70(5):465-76. PubMed ID: 26423144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [International reporting of adverse drug reactions. Final report of CIOMS ADR Working Group].
    Royer RJ; Benichou C
    Therapie; 1991; 46(3):173-8. PubMed ID: 1792648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Causality assessment for suspected DILI during clinical phases of drug development.
    Regev A; Seeff LB; Merz M; Ormarsdottir S; Aithal GP; Gallivan J; Watkins PB
    Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S47-56. PubMed ID: 25352327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of drug-induced liver injury in clinical practice.
    Lucena MI; García-Cortés M; Cueto R; Lopez-Duran J; Andrade RJ
    Fundam Clin Pharmacol; 2008 Apr; 22(2):141-58. PubMed ID: 18353109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute drug-induced hepatitis caused by albendazole.
    Choi GY; Yang HW; Cho SH; Kang DW; Go H; Lee WC; Lee YJ; Jung SH; Kim AN; Cha SW
    J Korean Med Sci; 2008 Oct; 23(5):903-5. PubMed ID: 18955802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Criteria for assessing granulocytic or platelet cytopenia caused by drugs. Results of consensus meetings].
    Solal-Céligny P; Benichou C; Boivin P; Castot A; Coulombel L; Danan G; Degos L; Evreux JC; Lagier G; Lavarenne J
    Nouv Rev Fr Hematol (1978); 1987; 29(4):265-70. PubMed ID: 3320952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Interstitial pneumopathies: criteria of drug side-effects. Results of consensus meetings].
    Fournier M; Camus P; Benichou C; Danan G; Begaud B; Castot A; Lagier G; Brune J; Pariente R; Chrétien J
    Presse Med; 1989 Sep 2-9; 18(27):1333-6. PubMed ID: 2529493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM.
    Scalfaro E; Streefkerk HJ; Merz M; Meier C; Lewis D
    Drug Saf; 2017 Aug; 40(8):715-727. PubMed ID: 28508325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.
    Woodworth T; Furst DE; Alten R; Bingham CO; Yocum D; Sloan V; Tsuji W; Stevens R; Fries J; Witter J; Johnson K; Lassere M; Brooks P
    J Rheumatol; 2007 Jun; 34(6):1401-14. PubMed ID: 17552067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Definitions and basic requirements for the use of terms for reporting adverse drug reactions (XII): collagen disorders and musculo-skeletal disorders.
    Council for International Organizations of Medical Sciences
    Pharmacoepidemiol Drug Saf; 1999 Mar; 8(2):141-5. PubMed ID: 15073939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Methodology of epidemiological studies in drug hepatotoxicity].
    Plomteux G
    Sem Hop; 1974 Jun; 50(28):1947-52. PubMed ID: 4374747
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of two clinical scales for causality assessment in hepatotoxicity.
    Lucena MI; Camargo R; Andrade RJ; Perez-Sanchez CJ; Sanchez De La Cuesta F
    Hepatology; 2001 Jan; 33(1):123-30. PubMed ID: 11124828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Definitions and basic requirements for the use of terms for reporting adverse drug reactions (X): gastrointestinal system disorders.
    Pharmacoepidemiol Drug Saf; 1998 Jul; 7(4):281-7. PubMed ID: 15073991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Definitions and basic requirements for the use of terms for reporting adverse drug reactions (XI): cardiovascular system disorders.
    Bankowski Z
    Pharmacoepidemiol Drug Saf; 1998 Sep; 7(5):351-7. PubMed ID: 15073983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Definitions and basic requirements for the use of terms for reporting adverse drug reactions (XIII): clinical pathology and general disorders.
    Council for International Organization of Medical Sciences
    Pharmacoepidemiol Drug Saf; 1999 May; 8(3):217-24. PubMed ID: 15073931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Harmonising adverse drug reaction terminology: the role of the Council for International Organizations of Medical Sciences.
    Venulet J; Bankowski Z
    Drug Saf; 1998 Sep; 19(3):165-72. PubMed ID: 9747664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Definitions of terms for reporting adverse drug reactions (IX): nervous system and psychiatric disorders.
    Council for International Organizations of Medical Sciences
    Pharmacoepidemiol Drug Saf; 1998 Jan; 7(1):39-49. PubMed ID: 15073745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Causality assessment in drug-induced liver injury.
    Hayashi PH
    Semin Liver Dis; 2009 Nov; 29(4):348-56. PubMed ID: 19826968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.